Cargando…

Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)

Biopharmaceutical production processes often use mammalian cells in bioreactors larger than 10,000 L, where gradients of shear stress, substrate, dissolved oxygen and carbon dioxide, and pH are likely to occur. As former tissue cells, producer cell lines such as Chinese hamster ovary (CHO) cells sen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaugler, Lena, Mast, Yannic, Fitschen, Jürgen, Hofmann, Sebastian, Schlüter, Michael, Takors, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815078/
https://www.ncbi.nlm.nih.gov/pubmed/36619888
http://dx.doi.org/10.1002/elsc.202100161
_version_ 1784864275402063872
author Gaugler, Lena
Mast, Yannic
Fitschen, Jürgen
Hofmann, Sebastian
Schlüter, Michael
Takors, Ralf
author_facet Gaugler, Lena
Mast, Yannic
Fitschen, Jürgen
Hofmann, Sebastian
Schlüter, Michael
Takors, Ralf
author_sort Gaugler, Lena
collection PubMed
description Biopharmaceutical production processes often use mammalian cells in bioreactors larger than 10,000 L, where gradients of shear stress, substrate, dissolved oxygen and carbon dioxide, and pH are likely to occur. As former tissue cells, producer cell lines such as Chinese hamster ovary (CHO) cells sensitively respond to these mixing heterogeneities, resulting in related scenarios being mimicked in scale‐down reactors. However, commonly applied multi‐compartment approaches comprising multiple reactors impose a biasing shear stress caused by pumping. The latter can be prevented using the single multi‐compartment bioreactor (SMCB) presented here. The exchange area provided by a disc mounted between the upper and lower compartments in a stirred bioreactor was found to be an essential design parameter. Mimicking the mixing power input at a large scale on a small scale allowed the installation of similar mixing times in the SMCB. The particularities of the disc geometry may also be considered, finally leading to a converged decision tree. The work flow identifies a sharply contoured operational field comprising disc designs and power input to install the same mixing times on a large scale in the SMCB without the additional shear stress caused by pumping. The design principle holds true for both nongassed and gassed systems.
format Online
Article
Text
id pubmed-9815078
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98150782023-01-05 Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB) Gaugler, Lena Mast, Yannic Fitschen, Jürgen Hofmann, Sebastian Schlüter, Michael Takors, Ralf Eng Life Sci Research Articles Biopharmaceutical production processes often use mammalian cells in bioreactors larger than 10,000 L, where gradients of shear stress, substrate, dissolved oxygen and carbon dioxide, and pH are likely to occur. As former tissue cells, producer cell lines such as Chinese hamster ovary (CHO) cells sensitively respond to these mixing heterogeneities, resulting in related scenarios being mimicked in scale‐down reactors. However, commonly applied multi‐compartment approaches comprising multiple reactors impose a biasing shear stress caused by pumping. The latter can be prevented using the single multi‐compartment bioreactor (SMCB) presented here. The exchange area provided by a disc mounted between the upper and lower compartments in a stirred bioreactor was found to be an essential design parameter. Mimicking the mixing power input at a large scale on a small scale allowed the installation of similar mixing times in the SMCB. The particularities of the disc geometry may also be considered, finally leading to a converged decision tree. The work flow identifies a sharply contoured operational field comprising disc designs and power input to install the same mixing times on a large scale in the SMCB without the additional shear stress caused by pumping. The design principle holds true for both nongassed and gassed systems. John Wiley and Sons Inc. 2022-03-14 /pmc/articles/PMC9815078/ /pubmed/36619888 http://dx.doi.org/10.1002/elsc.202100161 Text en © 2022 The Authors. Engineering in Life Sciences published by Wiley‐VCH GmbH. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Gaugler, Lena
Mast, Yannic
Fitschen, Jürgen
Hofmann, Sebastian
Schlüter, Michael
Takors, Ralf
Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)
title Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)
title_full Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)
title_fullStr Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)
title_full_unstemmed Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)
title_short Scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (SMCB)
title_sort scaling‐down biopharmaceutical production processes via a single multi‐compartment bioreactor (smcb)
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815078/
https://www.ncbi.nlm.nih.gov/pubmed/36619888
http://dx.doi.org/10.1002/elsc.202100161
work_keys_str_mv AT gauglerlena scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb
AT mastyannic scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb
AT fitschenjurgen scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb
AT hofmannsebastian scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb
AT schlutermichael scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb
AT takorsralf scalingdownbiopharmaceuticalproductionprocessesviaasinglemulticompartmentbioreactorsmcb